Baird raised the firm’s price target on Maravai Lifesciences (MRVI) to $3 from $2 and keeps a Neutral rating on the shares. The firm updated its model following Q4 results which modeslty beat consensus.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MRVI: